RWC Asset Management LLP Has $241,000 Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

RWC Asset Management LLP increased its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 13.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,485 shares of the biopharmaceutical company’s stock after purchasing an additional 401 shares during the period. RWC Asset Management LLP’s holdings in Insmed were worth $241,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. CIBC Asset Management Inc boosted its position in Insmed by 3.5% during the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 149 shares during the last quarter. Abel Hall LLC raised its stake in Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares in the last quarter. Commerce Bank increased its stake in Insmed by 2.4% during the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 163 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 183 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Insmed by 3.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock worth $446,000 after purchasing an additional 186 shares during the last quarter.

Insider Buying and Selling

In other Insmed news, CFO Sara Bonstein sold 3,470 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total value of $227,979.00. Following the sale, the chief financial officer now directly owns 114,736 shares of the company’s stock, valued at approximately $7,538,155.20. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at $26,912,553.60. The trade was a 4.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 532,207 shares of company stock worth $41,400,465. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

INSM has been the subject of several research reports. Wells Fargo & Company increased their target price on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Truist Financial boosted their target price on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday. Finally, Guggenheim lifted their price target on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.00.

Insmed Stock Down 3.0 %

NASDAQ INSM opened at $81.06 on Monday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a fifty day moving average of $74.29 and a two-hundred day moving average of $73.61.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.